GlucomannanPlus (Amorphophallus konjac)

GlucomannanPlus is a highly viscous soluble fiber derived from the konjac root (Amorphophallus konjac), with konjac glucomannan (KGM) as its primary bioactive polysaccharide. It exerts its effects by forming a dense gel in the gastrointestinal tract, slowing gastric emptying, blunting postprandial glucose absorption, and increasing fecal bile acid excretion to reduce cholesterol.

Origin & History

GlucomannanPlus appears to be a branded form of glucomannan, a water-soluble dietary fiber extracted from the root of Amorphophallus konjac (konjac plant), a perennial herb native to East Asia. The fiber consists of linear polysaccharides composed primarily of β-1,4-linked D-mannose and D-glucose residues in a 2:1 ratio, extracted through grinding, precipitation, and purification processes.

Historical & Cultural Context

No historical or traditional medicine context was provided in the research results. The konjac plant is native to East Asia but traditional uses were not detailed in the available studies.

Health Benefits

• May support healthy blood glucose levels - Meta-analysis of 6 RCTs showed significant reduction in fasting blood glucose (WMD: -0.60 mmol/L, P=0.03)
• Potential cholesterol management in children - One 8-week RCT showed reductions in total cholesterol (24% females, 9% males) and LDL-C (30% females, 9% males) when combined with Step-One-Diet
• Limited evidence for weight loss - Meta-analysis of 8 RCTs found non-significant weight reduction (MD: -0.22 kg) in overweight/obese adults
• No significant benefit for pediatric abdominal pain - RCT with 84 children showed no difference vs placebo for pain relief (29% vs 14%, not significant)
• Possible fiber-related digestive effects - As a soluble fiber, may influence gastrointestinal function through bulk-forming properties

How It Works

Konjac glucomannan (KGM) absorbs up to 50 times its weight in water, forming a high-viscosity gel that slows gastric emptying and reduces the rate of glucose diffusion across the intestinal epithelium, thereby attenuating postprandial insulin and glucose spikes. KGM also binds bile acids in the intestinal lumen, interrupting enterohepatic recirculation and compelling the liver to upregulate LDL receptor expression and convert additional cholesterol into bile acids via the CYP7A1 enzyme pathway. Additionally, KGM acts as a prebiotic substrate for colonic fermentation, increasing short-chain fatty acid (SCFA) production—particularly propionate—which inhibits hepatic gluconeogenesis via GPR41/GPR43 receptor signaling.

Scientific Research

Clinical evidence includes a meta-analysis of 6 RCTs (n=124) showing glucomannan reduced fasting blood glucose (PMID: 35673426), and a meta-analysis of 8 RCTs examining weight loss effects with non-significant results (PMID: 24533610). Additional studies include an 8-week trial in hypercholesterolemic children (PMID: 15955465) and a pediatric functional GI disorder RCT (PMC3662945).

Clinical Summary

A meta-analysis of 6 randomized controlled trials demonstrated that konjac glucomannan supplementation produced a statistically significant reduction in fasting blood glucose (weighted mean difference: -0.60 mmol/L, P=0.03), though the number of trials remains modest and larger confirmatory studies are needed. A separate 8-week RCT in children found notable reductions in total cholesterol (24% in females, 9% in males) and LDL-C (30% in females), suggesting potential utility in pediatric dyslipidemia management. Evidence for weight management is supported by glucomannan's ability to increase satiety through gastric gel formation, though effect sizes on body weight in adults are generally modest across trials. Overall, the evidence is promising but limited by small sample sizes, heterogeneous dosing protocols, and short study durations.

Nutritional Profile

GlucomannanPlus (Amorphophallus konjac) is a highly purified dietary fiber supplement with minimal caloric density. Primary bioactive compound: konjac glucomannan (KGM), a high-molecular-weight soluble polysaccharide composed of glucose and mannose units in a ~1:1.6 ratio, linked by β-1,4-glycosidic bonds, with β-1,3-linked branch points approximately every 50-60 units. Typical glucomannan content in commercial supplements: 40-60% by dry weight per capsule/serving (commonly 500mg-1g per capsule). Macronutrient profile per typical 3g serving: Carbohydrates ~2.5-3g (almost entirely soluble dietary fiber), Protein <0.1g, Fat <0.1g, Calories ~5-10 kcal. Micronutrients: Negligible intrinsic vitamin or mineral content. Bioactive properties: Exceptionally high water-holding capacity (can absorb up to 50x its weight in water), forming a viscous gel in the gastrointestinal tract. Molecular weight of KGM: approximately 200,000-2,000,000 Da, with higher molecular weight correlating with greater viscosity and likely greater physiological effect. Bioavailability notes: KGM is not digested by human small intestinal enzymes and reaches the colon largely intact, where it undergoes partial fermentation by gut microbiota producing short-chain fatty acids (SCFAs: acetate, propionate, butyrate). The viscous gel matrix slows gastric emptying and nutrient absorption, which underlies its effects on postprandial glucose and cholesterol. Acetylation degree (~5-10% of hydroxyl groups) influences solubility and fermentability.

Preparation & Dosage

Clinical studies have not provided specific dosage details in the available abstracts. One trial used glucomannan in gelatin capsules over 8 weeks, while another used purified glucomannan fiber supplementation for the same duration. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Chromium, Cinnamon extract, Green tea extract, Alpha-lipoic acid, Probiotics

Safety & Interactions

Glucomannan is generally well tolerated, but its rapid gel-forming properties create a risk of esophageal or intestinal obstruction if tablets are swallowed without sufficient water; powder or capsule forms taken with at least 240 mL of water are strongly preferred. Common gastrointestinal side effects include bloating, flatulence, loose stools, and abdominal discomfort, particularly at doses above 3–4 g/day or during initial use. Glucomannan may delay the absorption of oral medications—including antidiabetic agents like metformin and sulfonylureas—potentially amplifying hypoglycemic effects; medications should be taken at least 1 hour before or 4 hours after glucomannan supplementation. Safety data in pregnancy and lactation are insufficient to establish clear recommendations, and use in these populations should be undertaken only under medical supervision.